Motley Fool July 31, 2020
Moderna had a head start in advancing its COVID-19 vaccine into clinical testing. But Pfizer is ahead in some important ways.
There’s one U.S. company developing a novel-coronavirus vaccine candidate that’s probably been in the headlines more than any other. Moderna (NASDAQ:MRNA) made waves earlier this year with its rapid development of a COVID-19 vaccine candidate that uses messenger RNA (mRNA). The mRNA spurs the ribosomes to generate antigens that are like the spike protein in SARS-CoV-2 (the novel coronavirus), then the body responds by producing antibodies against it.
Moderna quickly established itself as a leader in the race to develop a COVID-19 vaccine. Its stock has skyrocketed as a result, more than quadrupling so far this year.
Today's Sponsors
Today's Sponsor